Novartis raises guidance as new drugs offset pipeline setbacks
- Novartis is a pure-play innovative medicines company.
- The company raised its full-year 2026 guidance after hitting a 41.6% core margin in the third quarter.
- Kisqali continues to grow rapidly in the early breast cancer market.
- Two late-stage pipeline drugs recently failed Phase 3 trials, triggering a massive impairment charge.
- Key growth drivers face Medicare price negotiation for 2028.
Execution meets pipeline failure
The bull case centers on excellent commercial execution. Novartis raised its full-year 2026 guidance following a strong third quarter, driven by Kisqali in early breast cancer and the launch of Rhapsido. The company even pushed its peak sales target for Rhapsido beyond USD 4 billion.
However, the long-term pipeline just took a major hit. The highly anticipated Avidity asset del-zota failed its Phase 3 trial, forcing Novartis to take a USD 1.9 billion impairment charge. Another late-stage drug, pelacarsen, also failed its Phase 3 study. This puts more pressure on current products to maintain growth.
On top of pipeline misses, policy risk remains high. Novartis agreed in December 2025 to launch future medicines with comparable prices across high-income countries. CMS also picked Cosentyx, Kisqali, and Xolair for Medicare price negotiation for 2028.
Finn lands near the middle because both sides are very real. Novartis is squeezing more profit out of its current portfolio, hitting a 41.6% core margin. Yet investors are paying for a company that must navigate price caps and clinical failures to keep growing.
Patents, launches, and discipline
Novartis makes money by discovering, buying, testing, manufacturing, and selling patented drugs. The company focuses on specialty areas with high unmet needs instead of crowded mass markets where rebates can eat into prices.
The current plan targets more than 5% average annual sales growth through 2028. Management is trying to reach that by scaling drugs such as Kisqali, Kesimpta, Pluvicto, Scemblix, and Rhapsido. Strong sales helped the company reach a 41.6% core operating margin in the third quarter of 2026.
The model breaks when patents expire, policy limits pricing, or clinical trials fail. Generic copies have already hurt older drugs. The recent Phase 3 failures of del-zota and pelacarsen show the high risk of relying on acquired pipeline assets to replace expiring patents.
Novartis is also spending heavily to reduce supply chain risk. Management is investing USD 23 billion with a goal of making 100% of key United States products end-to-end inside the country.
The drugs that matter
Cosentyx
Cosentyx is a major immunology drug with USD 6.7 billion of 2025 sales. It is still important, but Medicare price negotiation for 2028 is a clear risk.
Kisqali
Kisqali is a breast cancer drug and one of Novartis's biggest growth engines. It recently crossed USD 1 billion in quarterly United States sales.
Kesimpta
Kesimpta treats multiple sclerosis. It reached USD 4.4 billion of 2025 sales and continues to grow strongly.
Pluvicto
Pluvicto is a radioligand therapy for prostate cancer. It uses a targeted radioactive payload to attack cancer cells and is expanding into earlier treatment settings.
Scemblix
Scemblix treats chronic myeloid leukemia. The company expects it to reach front-line leadership in the United States in late 2026.
Entresto
Entresto remains important in heart failure, but it is now a managed decline story in the United States. The drug accepted a maximum fair price under the IRA for 2026, and generics entered the market in mid-2025.
Rhapsido
Rhapsido is an oral BTK inhibitor for chronic spontaneous urticaria. Management recently upgraded its peak sales guidance to over USD 4 billion.
Where sales come from
The mix uses 2025 net sales from continuing operations in the Form 20-F. Novartis reports as one innovative medicines company, making these geographic sales buckets rather than separate profit segments.
What could go wrong
United States drug price cuts
High impact · High oddsCosentyx, Kisqali, and Xolair were selected for Medicare price negotiation for 2028. Entresto already accepted a maximum fair price for 2026. If negotiated prices are harsh, growth drugs could be worth less than investors expect.
Pipeline execution failures
High impact · Medium oddsNovartis took a USD 1.9 billion impairment charge in the third quarter of 2026 after its Avidity asset del-zota failed a Phase 3 trial. Pelacarsen also failed its Phase 3 study, wiping out expected future revenues.
Generic erosion in 2026
Medium impact · High oddsUnited States generics for Entresto, Promacta, and Tasigna entered the market in mid-2025. Older products continue to drag on the newer portfolio.
Global launch price cap
High impact · Medium oddsNovartis agreed with the United States administration to launch future medicines with comparable prices across high-income countries. That could limit the old playbook of charging much higher prices for new drugs.
In one breath
What does Novartis do?
Novartis develops and sells patented medicines. Its main focus areas are cardiovascular, renal and metabolic disease, immunology, neuroscience, and oncology.
Why did Novartis take a USD 1.9 billion impairment?
The Avidity asset del-zota failed its Phase 3 HARBOR trial. This forced the company to write down its value and delay launch timelines.
What are the biggest Novartis growth drugs?
Kisqali, Kesimpta, Pluvicto, Scemblix, and Rhapsido are the clearest current growth drivers. Kisqali and Rhapsido have shown especially strong momentum recently.
Why is Novartis stock not scored higher?
The company is executing well, but the price and pipeline risks are real. Key drugs face United States Medicare price negotiation, and recent Phase 3 clinical failures hurt the long-term outlook.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Novartis AG in Finn's Drug Manufacturers - General industry ranking.

